Breaking Bias in Clinical Trials: Sabine Oertelt-Prigione and Brandon Turner Share Insights on Diversity, Sex, and Gender Representation
Flora Peyvandi posted on X:
”Tackling biases in clinical trials to ensure diverse representation and effective outcomes.”
Professor Sabine Oertelt-Prigione has been working in the field of sex and gender-sensitive research for the last 15 years. Her current work is focused on trying to understand how sex and gender-sensitive medicine can be successfully implemented in research and practice as well as methods to investigate gender in medical research.
Dr. Brandon Turner is a resident physician in the Department of Radiation Oncology at Massachusetts General Hospital and Brigham and Women’s Hospital. He has conducted and is involved in numerous studies looking to evaluate race and ethnicity reporting and representation in clinical trials.
In this interview for Nature Communications, Sabine Oertelt-Prigione, and Brandon Turner share their knowledge about the biases that can occur in clinical trials and how they can be minimized.
Read the full article here.
Latest news in the world of research featured in Hemostasis Today.
-
Aug 26, 2026, 17:09Kemal Karaagac: NOACs May Offer Cognitive and Clinical Benefits in AF With Alzheimer’s Disease
-
Aug 26, 2026, 16:53Chokri Ben Lamine: Antiphospholipid Syndrome After Kidney Transplantation
-
Aug 26, 2026, 16:32Kai Rejeski: Why TP53 Mutations May Define a Higher-Risk CAR-T Population
-
Aug 26, 2026, 16:20Ons Marsit: Impact of Electroanatomical Mapping on Pentaspline Pulsed Field Ablation
-
Aug 26, 2026, 16:18Sam Mbunya: Celebrating Cyrus Njuguna Githinji’s New Leadership Role in Haemophilia Care
-
Aug 26, 2026, 15:48Melissa Hollo: Postpartum Depression is More Than the “Baby Blues”
-
Aug 26, 2026, 15:46Raghavendra Rao: The Link Between Neuropathy and Chronic Venous Disease
-
Aug 26, 2026, 15:43Laurent Bertoletti: Long Term Benefits and Safety of Rehabilitation in Pulmonary Arterial Hypertension
-
Aug 26, 2026, 15:41Tamer Hellou: Chromosome 1q Gain Signals High Long-Term Risk in AL Amyloidosis